Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2026 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizioAcceptable Use
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to Reports
Fundraising

Cushman & Wakefield

Cushman & Wakefield Raises $10B in Public

225 W Wacker Drive, Chicago, IL 60606January 1, 20242 min read
Employees
50000+

Cushman & Wakefield Raises $10B in Public


Cushman & Wakefield has successfully raised $10B in a Public at a $12B valuation led by Public.


Company Overview


Cushman & Wakefield is a Real Estate company headquartered in 225 W Wacker Drive, Chicago, IL 60606, founded in 1917 with 50000+ employees.


Commercial real estate services firm


Fundraising Details


  • Amount Raised: $10B
  • Round Type: Public
  • Valuation: $12B
  • Date: 2024-01-01
  • Investors: Public

About Cushman & Wakefield


Commercial real estate services firm The company is positioned in the Real Estate sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 225 W Wacker Drive, Chicago, IL 60606
  • Founded: 1917
  • Team Size: 50000+
  • Industry: Real Estate

What This Means


This funding round demonstrates strong investor confidence in Cushman & Wakefield's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Real Estate sector continues to attract significant investment as companies innovate to meet evolving market demands. Cushman & Wakefield's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $12B valuation marks an important milestone for Cushman & Wakefield, positioning the company among notable players in the Real Estate industry.


Looking Ahead


With this new capital, Cushman & Wakefield is well-positioned to execute on its growth strategy and continue building innovative solutions in the Real Estate space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Cushman & Wakefield, visit their headquarters at 225 W Wacker Drive, Chicago, IL 60606.

Company Info

Headquarters
225 W Wacker Drive, Chicago, IL 60606
Founded
1917
Team Size
50000+

Topics

Fundraising(2912)Public(771)Real EstateCushman & Wakefield

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free